Common TitleVIKING
Official Title A Pilot Study to Assess the Antiviral Activity of Dolutegravir (GSK1349572) Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Phase Phase II
ClinicalTrials.gov NCT00950859
Treatments
Dolutegravir

Dolutegravir
Tradename:TivicayOther Names:DTGClass:Integrase Inhibitors (INSTI)Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryViiV Healthcare
References
- Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207:740-8.